Literature DB >> 21538428

Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum.

Alberto Briganti1, Nazareno Suardi, Paolo Capogrosso, Niccolò Passoni, Massimo Freschi, Ettore di Trapani, Andrea Gallina, Umberto Capitanio, Firas Abdollah, Manuela Tutolo, Marco Bianchi, Andrea Salonia, Luigi Filippo Da Pozzo, Francesco Montorsi, Patrizio Rigatti.   

Abstract

BACKGROUND: The aim of this study was to map the nodal metastases distribution in patients with high-risk prostate cancer (PCa) treated with extended pelvic lymph node dissection (ePLND) and retroperitoneal lymph node dissection (rLND) at the time of radical prostatectomy (RP).
MATERIALS AND METHODS: This prospective mapping study included 19 patients with high-risk PCa (sharing at least two out of the three following parameters: PSA >20 ng/ml, cT3, biopsy Gleason score ≥8). All patients were treated with RP, ePLND (removal of the obturator, hypogastric, external iliac, presacral, and common iliac lymph nodes) and rLND (removal of para-aortal/para-caval and inter-aorto-caval lymph nodes) by a single surgeon. All patients signed an informed consent highlighting the absence of clinical data supporting the benefit of this surgical approach.
RESULTS: Overall, 18 out of 19 patients (94.7%) had pelvic lymph node invasion. The most commonly affected pelvic nodal landing site was obturator (88.8%), followed by external iliac (83.3%), common iliac (77%), hypogastric (44.4%), and presacral (33.3%). Moreover, 14 (77.8%) patients also had involvement of retroperitoneal lymph nodes. Only patients with positive common iliac lymph nodes having at least five positive lower pelvic lymph nodes (n = 14), also had invariably positive retroperitoneal lymph nodes. No patients with negative common iliac lymph nodes had positive retroperitoneal lymph nodes.
CONCLUSIONS: PCa lymphatic spread ascends from the pelvis up to the retroperitoneum invariably through common iliac lymph nodes. PCa lymphatic spread can be divided in two main levels: pelvic and common iliac plus retroperitoneal lymph nodes.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21538428     DOI: 10.1002/pros.21420

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  18 in total

1.  Current status of pelvic lymph node dissection in prostate cancer.

Authors:  Ilija Aleksic; Tyler Luthringer; Vladimir Mouraviev; David M Albala
Journal:  J Robot Surg       Date:  2013-12-11

Review 2.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

Review 3.  Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.

Authors:  Michele Colicchia; Vidit Sharma; Firas Abdollah; Alberto Briganti; R Jeffrey Karnes
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 4.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

5.  Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.

Authors:  Stefan A Koerber; Gerald Stach; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Peter L Choyke; Uwe Haberkorn; Juergen Debus; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-07-13       Impact factor: 11.082

6.  Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.

Authors:  Carlo A Bravi; Nicola Fossati; Giorgio Gandaglia; Nazareno Suardi; Elio Mazzone; Daniele Robesti; Daniar Osmonov; Klaus-Peter Juenemann; Luca Boeri; R Jeffrey Karnes; Alexander Kretschmer; Alexander Buchner; Christian Stief; Andreas Hiester; Alessandro Nini; Peter Albers; Gaëtan Devos; Steven Joniau; Hendrik Van Poppel; Shahrokh F Shariat; Axel Heidenreich; David Pfister; Derya Tilki; Markus Graefen; Inderbir S Gill; Alexander Mottrie; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2020-07-02       Impact factor: 24.267

7.  Optimizing the management of high-risk, localized prostate cancer.

Authors:  Debasish Sundi; Byong Chang Jeong; Seung Bae Lee; Misop Han
Journal:  Korean J Urol       Date:  2012-12-20

8.  Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Authors:  Nicola Fossati; Nazareno Suardi; Giorgio Gandaglia; Carlo A Bravi; Matteo Soligo; R Jeffrey Karnes; Shahrokh Shariat; Antonino Battaglia; Wouter Everaerts; Steven Joniau; Hendrik Van Poppel; Nieroshan Rajarubendra; Inderbir S Gill; Alessandro Larcher; Alexander Mottrie; Maximilian Schmautz; Axel Heidenreich; Almut Kalz; Daniar Osmonov; Klaus-Peter Juenemann; Annika Herlemann; Christian Gratzke; Christian Stief; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2018-10-06       Impact factor: 24.267

Review 9.  Extended lymph node dissection in robotic radical prostatectomy: Current status.

Authors:  Sameer Chopra; Mehrdad Alemozaffar; Inderbir Gill; Monish Aron
Journal:  Indian J Urol       Date:  2016 Apr-Jun

10.  Comparing nodal versus bony metastatic spread using tumour phylogenies.

Authors:  Stefano Mangiola; Matthew K H Hong; Marek Cmero; Natalie Kurganovs; Andrew Ryan; Anthony J Costello; Niall M Corcoran; Geoff Macintyre; Christopher M Hovens
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.